Otezla (apremilast) is an oral tablet commonly used to treat psoriatic arthritis in adults. Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common ...

Psoriatic arthritis is most likely to develop in people ages 30 to 50, according to the National Psoriasis Foundation. That means you have many decades of managing the autoimmune condition ahead of ...

Anyone can develop psoriatic arthritis, but it’s most common in people who already have psoriasis, affecting about 30 percent of people with the skin condition. Whether you’re managing just psoriatic ...

With psoriatic arthritis (PsA), there's a lot you can do to take care of your body and feel more in control of your symptoms. Simple self-care routines can help prevent and manage flare-ups, help you ...

If you’re among the millions of people living with psoriasis and psoriatic arthritis (PsA), you’re no stranger to the considerable toll the autoimmune condition can take on your quality of life.

Dr Philip Mease explores how modern imaging tools are reshaping the understanding of joint damage and progression in ...

When the immune system mistakenly attacks healthy cells in both the skin and joints, the result is psoriatic arthritis—a challenging condition that affects approximately 1 million Americans. While ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque ...

Joni Kazantzis was diagnosed with psoriasis at 15 and received a psoriatic arthritis diagnosis during the pandemic. She created a blog and social platform to offer the guidance she once ...

At week 16, both trials showed a significantly greater proportion of deucravacitinib-treated patients achieved ACR20 response compared with placebo. Topline data were announced from two phase 3 trials ...

The FDA has approved Johnson & Johnson’s TREMFYA for children aged 6+ weighing at least 40 kg with moderate to severe plaque psoriasis or active psoriatic arthritis.